When operational capital and acquisition capital draw on the same facility, the allocation meeting has already been decided before anyone walks in.
Ask an operating partner whether they have systematically underinvested in their portfolio companies’ equipment base and you will get an immediate and sincere no. Ask them to name the last three capital allocation decisions at a platform company and you will usually get three add-on acquisitions.
Both answers are honest. That is what makes the pattern so durable.
At most sponsor-backed platforms, operational capital and acquisition capital come from the same place — the credit facility established at the platform level, sized against EBITDA, and governed by covenants constraining total leverage. Under that architecture, funding a $2.8 million automation program and funding a $2.8 million add-on are not independent decisions. They are competing claims on one finite pool.
It is the thesis. It adds revenue, adds EBITDA, and advances the platform story that gets told at exit. In a buy-and-build committee, it wins — every time.
An operational improvement with an 18–24 month payback that would visibly lift EBITDA — and, crucially, can wait. So it waits.
Put those two options in front of an investment committee pursuing a buy-and-build thesis and the outcome is not close. The acquisition is the thesis. It adds revenue, it adds EBITDA, it advances the platform story that will be told at exit, and it is the reason the fund underwrote the deal in the first place. The automation program is an operational improvement that improves margin over eighteen to twenty-four months and — crucially — can wait.
It can wait. That is exactly the problem. It waits, and then it waits again at the next allocation decision, and the next.
Three years on, the pattern has produced a specific and recognizable outcome: a platform that has grown substantially by acquisition, running on an equipment base that has not been meaningfully reinvested in since the original transaction. The revenue chart looks excellent. The margin chart does not, and nobody can quite say why.
The reason is usually visible on the shop floor. The integration synergies that justified the roll-up — consolidating production, standardizing processes, moving volume to the most efficient facility — depend on operational capability the platform never funded. You cannot consolidate three facilities into two if the surviving facility lacks the capacity to absorb the volume, and adding that capacity was the project that lost to the add-on in Q3 of year two.
What makes this genuinely hard is that no individual decision was wrong. Each add-on was accretive. Each deferral was defensible. The failure is structural rather than judgmental, which is why better prioritization does not fix it. As long as both needs draw on the same facility, the allocation meeting resolves the same way every time, regardless of what anyone intends.
The resolution is to stop treating these as the same kind of capital, because they are not.
An add-on acquisition is a leveraged bet on integration and multiple expansion. The collateral is goodwill and a customer list. The risk is execution risk. It belongs on a credit facility, priced accordingly.
A machining cell, a packaging line, an automated material handling system — these are physical assets with identifiable value, observable secondary markets, defined useful lives, and a direct productive contribution. They are among the most financeable things a business owns. Routing them through a leveraged credit facility, where they consume acquisition capacity and add covenant pressure, is a mismatch between the asset and the instrument.
Financed separately — outside the facility, without covenants, without consuming leverage capacity — the trade-off disappears entirely. The automation program and the add-on stop competing. Both happen. The allocation meeting becomes a sequencing conversation rather than a zero-sum one.
That is not a financing trick. It is recognizing that two capital needs with completely different risk characteristics were never supposed to be drawing on the same pool.
The timing consideration makes this more pressing than it has been. Distributions as a share of net asset value have stayed below 15 percent for four consecutive years, an industry record. Hold periods have stretched toward seven years. Something on the order of 32,000 unsold companies worth roughly $3.8 trillion are sitting in funds waiting for an exit environment that has been forecast to improve since 2023 and has not.
Which means the platform acquired in 2021 on a five-year hold assumption is now looking at eight or nine, and every year of deferred operational investment in that period compounds into the condition of the asset at sale. A buyer’s diligence team will find the equipment schedule. They always do.
There is a version of this article that argues sponsors should spend more on their portfolio companies. That is not the argument. The argument is narrower and considerably more actionable: sponsors should stop making operational investment compete with acquisition capital for the same dollar, because that competition has a predetermined winner and it has been quietly shaping portfolio outcomes for years.
Most operating partners cannot produce, on request, a number for what operational capital has been deferred across the portfolio since acquisition. That inability is itself the finding. The exercise usually reveals that the deferred investment is smaller than assumed, and that what it would restore at exit is considerably larger.
First National Capital Corporation finances portfolio company equipment outside the credit facility — non-dilutive, covenant-free, and without consuming acquisition capacity. More than $4.5 billion funded across sponsor-backed transactions.